Skip to main content
SpringerLink
Log in

Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Special Cases?

  • Chapter
  • First Online:
Advances in Vascular Medicine

  • 890 Accesses

Abstract

Is connective tissue disease (CTD) associated pulmonary arterial hypertension (CTPAH) a distinct entity or group of conditions, or merely a form of idiopathic pulmonary arterial hypertension (iPAH) perhaps triggered by the immunological perturbations seen in these conditions? In arguing for causality as is recognized for HIV-associated pulmonary arterial hypertension (PAH), fulfilling Hill’s criteria for causation is quite complex,1 especially because failure to meet any of the criteria does not preclude a cause-effect relationship.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.

    CAS  PubMed  Google Scholar 

  2. Yoshida A, Katayama M. Pulmonary hypertension in patients with connective tissue diseases. Nippon Rinsho. 2001;59(6):1164-1167.

    CAS  PubMed  Google Scholar 

  3. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest. 1996;110:1515-1519.

    Article  CAS  PubMed  Google Scholar 

  4. Humbert M, Carouat A, Bertocchi M, et al. ItinerAIR-HTAP a French national prospective registry of pulmonary arterial hypertension. Am J Respir Crit Care. 2004;169:A169.

    Google Scholar 

  5. Wigley F, Mayes M, Limia J, et al. The point prevalence of undiagnosed pulmonary arterial hypertension in patients with connective tissue disease (CTD) attending community based rheumatology clinics (Uncover). ACR Annual Scientific Meeting 2004 Presentation No 1057.

    Google Scholar 

  6. Dawson JK, Goodson NG, Graham DR, Lynch MP. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology. 2000;39(12):1320-1325.

    Article  CAS  PubMed  Google Scholar 

  7. Marasini B, Massarotti M, Cossutta R, et al. Pulmonary hypertension in autoimmune rheumatic diseases. Rheumatismo. 2005;57:114-118.

    CAS  Google Scholar 

  8. Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med. 1978;64:998-1004.

    Article  CAS  PubMed  Google Scholar 

  9. Mukerjee D, St. George D, Coleiro B, et al. Prevalence & outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088-1093.

    Article  CAS  PubMed  Google Scholar 

  10. Pietra G, Capron F, Stewart S, et al. Pathological assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43 suppl 12:25S-32S.

    Article  Google Scholar 

  11. Cool C, Kennedy D, Voelkel N, Tuder R. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol. 1997;28:434-442.

    Article  CAS  PubMed  Google Scholar 

  12. Tuder R, Groves B, Badesch D, Voelkel N. Exuberent endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144:275-285.

    CAS  PubMed  Google Scholar 

  13. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246-2255.

    Article  PubMed  Google Scholar 

  14. Vlachoyiannopoulos PG, Dafni UG, Pakas I, et al. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis. 2000;59(5):359-367.

    Article  CAS  PubMed  Google Scholar 

  15. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheum. 1996;35:989-993.

    Article  CAS  Google Scholar 

  16. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;23:344-350.

    Article  Google Scholar 

  17. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003;167:580-586.

    Article  PubMed  Google Scholar 

  18. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.

    Article  CAS  PubMed  Google Scholar 

  19. Simonneau G, Barst RJ, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomised, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800-804.

    PubMed  Google Scholar 

  20. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.

    Article  CAS  PubMed  Google Scholar 

  21. Galiè N, Umbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue in patients with pulmonary arterial hypertension: a randomised, double-blind, ­placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496-1502.

    Article  PubMed  Google Scholar 

  22. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:441-447.

    Article  PubMed  Google Scholar 

  23. Ghofani A for the Sildenafil 1140 study group. Efficacy and safety of sildenafil in pulmonary arterial hypertension: results of a multinational randomized, double blind placebo controlled trial. Am Coll Chest Phys. 2004.

    Google Scholar 

  24. Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart. 2006;92(7):926-932.

    Article  CAS  PubMed  Google Scholar 

  25. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35-42.

    Article  CAS  PubMed  Google Scholar 

  26. Bordron A, Dueymes M, Levy Y, et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 1998;101:2029-2035.

    Article  CAS  PubMed  Google Scholar 

  27. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358-363.

    Article  CAS  PubMed  Google Scholar 

  28. Nicholls M, Taraseviciene-Stewart L, Rai P, et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J. 2005;26:1110-1118.

    Article  Google Scholar 

  29. Humbert M, Nunes H, Sitbon O, Parent P, Hervé P, Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med. 2001;22:459-475.

    Article  CAS  PubMed  Google Scholar 

  30. Lesprit P, Godeau B, Authier FJ, et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med. 1998;157:907-911.

    CAS  PubMed  Google Scholar 

  31. Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest. 2002;122:1668-1673.

    Article  PubMed  Google Scholar 

  32. Isern RA, Yaneva M, Weiner E, et al. Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am J Med. 1992;93:307-312.

    Article  CAS  PubMed  Google Scholar 

  33. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151:1628-1631.

    CAS  PubMed  Google Scholar 

  34. Winslow TM, Ossipov MA, Fazio GP, et al. Five year follow up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J. 1995;129:510-515.

    Article  CAS  PubMed  Google Scholar 

  35. Mukerjee D, Kingdon E, VanDerPump M, Coghlan J. Pathophysiological insights from a case of reversible pulmonary hypertension. J Royal Soc Med. 2003;96:403-404.

    Article  CAS  Google Scholar 

  36. Pacioccio G, Bossone E, Erba H, Rubenfire M. Reversible pulmonary hypertension in POEMS syndrome - another ethiology of triggered pulmonary vasculopathy. Can J Cardiol. 2000;16:1007-1012.

    Google Scholar 

  37. Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension secondary to connective tissue diseases. Thorax. 1999;54:273-277.

    Article  CAS  PubMed  Google Scholar 

  38. Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN. 40-O-(2-Hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. AmJ Resp Crit Care Med. 2001;163:498-502.

    CAS  Google Scholar 

  39. Tormey VJ, Bunn CC, Denton C, et al. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology. 2001;40:1157-1162.

    Article  CAS  PubMed  Google Scholar 

  40. Asherton RA, Oakley CM. Pulmonary hypertension and systemic lupus erythematosis. J Rheumatol. 1986;13:1-5.

    Google Scholar 

  41. Negi VS, Tripathy NK, Misra R, et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischaemia and pulmonary arterial hypertension. J Rheumatol. 1998;25:462-466.

    CAS  PubMed  Google Scholar 

  42. Fritzler MJ, Hart DA, Wilson D, et al. Antibodies to fibrin bound tissue type plasminogen activator antibodies in systemic sclerosis. J Rheumatol. 1995;22:1688-1693.

    CAS  PubMed  Google Scholar 

  43. Morse JH, Barst RJ, Fotino M, et al. Primary pulmonary hypertension, tissue plasminogen activator antibodies and HLA-DQ7. Am J Respir Crit Care Med. 1997;155:274-278.

    CAS  PubMed  Google Scholar 

  44. Martin L, Paulus JD, Ryan P, et al. Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and histone. Ann Rheum Dis. 1993;52:780-784.

    Article  CAS  PubMed  Google Scholar 

  45. Grigolo B, Mazzeti I, Meliconi R, et al. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol. 2000;121:539-543.

    Article  CAS  PubMed  Google Scholar 

  46. Morse J, Barst R, Horn E, et al. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol. 2002;29:2379-2381.

    PubMed  Google Scholar 

  47. Susol E, Rands AL, Herrick M, et al. Association of markers for TGFbeta3, TGFbeta2 and TIMPI1 with systemic sclerosis. Rheumatology. 2000;39:13332-13336.

    Article  Google Scholar 

  48. Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Nat Acad Sci U S A. 2002;99(6):3908-3913.

    Article  CAS  Google Scholar 

  49. Yamane K, Ihn H, Kubo M, Tamaki K. Increased transcriptional activities of transforming growth factor beta receptors in scleroderma fibroblasts. Arthritis Rheum. 2002;46(9):2421-2428.

    Article  CAS  PubMed  Google Scholar 

  50. Leask A, Abraham DJ, Finlay DR, et al. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum. 2002;46(7):1857-1865.

    Article  CAS  PubMed  Google Scholar 

  51. Kubo M, Ihn H, Yamane K, Tamaki K. Upregulated expression of TGFβ receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol. 2002;29:2558-2564.

    CAS  PubMed  Google Scholar 

  52. Dorfmüller P, Zarka V, Durand-Gasselin I, et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Resp Crit Care Med. 2002;165:534-539.

    PubMed  Google Scholar 

  53. Kim NHS, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Therapeut. 2002;7:9-19.

    Article  CAS  Google Scholar 

  54. Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud’s phenomenon and systemic sclerosis. Intern Med. 1994;33:579-582.

    Article  CAS  PubMed  Google Scholar 

  55. Maeda M, Kachi H, Takagi H, Kitajima Y. Is there circadian variation of plasma endothelin (ET-1) in patients with systemic scleroderma (SSc)? J Dermatol Sci. 1997;16:38-44.

    Article  CAS  PubMed  Google Scholar 

  56. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localisation of endothelin-1 and its binding sites in scleroderma skin. J Rheum. 1994;21:1268-1276.

    CAS  PubMed  Google Scholar 

  57. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.

    Article  CAS  PubMed  Google Scholar 

  58. Yamane K, Miyauchi T, Suzuki N, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rehum. 1992;19:1566-1571.

    CAS  Google Scholar 

  59. Okawa-Takatsuji M, Aotsuka S, Fujinami M, et al. Upregulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol. 1999;116:174-180.

    Article  CAS  PubMed  Google Scholar 

  60. Tamby M, Chanseaud Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax. 2005;60:765-772.

    Article  CAS  PubMed  Google Scholar 

  61. Tanaka E, Harigai M, Tanaka M, et al. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol. 2002;29(2):282-287.

    PubMed  Google Scholar 

  62. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus. 2000;9(5):338-342.

    Article  CAS  PubMed  Google Scholar 

  63. Michels H. Course of mixed connective tissue disease in children. Ann Med. 1997;29(5):359-364.

    Article  CAS  PubMed  Google Scholar 

  64. Alpert MA, Goldberg SH, Singsen BH, et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation. 1983;68(6):1182-1193.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Royal Free and University College Medical School, Gower Street, WC1E 6BT, London, UK

    Gerry Coghlan

Authors
  1. Gerry Coghlan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerry Coghlan .

Editor information

Editors and Affiliations

  1. University College London, Gower Street, London, WC1E 6BT, United Kingdom

    David Abraham

  2. The Royal Free & Univ College Med School, Gower Street, London, WC1E 6BT, United Kingdom

    Handler Clive

  3. University College London, Gower Street, London, WC1E 6BT, United Kingdom

    Michael Dashwood

  4. The Royal Free & Univ College Med School, Gower Street, London, WC1E 6BT, United Kingdom

    Gerry Coghlan

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London

About this chapter

Cite this chapter

Coghlan, G. (2009). Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Special Cases?. In: Abraham, D., Clive, H., Dashwood, M., Coghlan, G. (eds) Advances in Vascular Medicine. Springer, London. https://doi.org/10.1007/978-1-84882-637-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-84882-637-3_18

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84882-636-6

  • Online ISBN: 978-1-84882-637-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation